Healio (7/29, Downey) reports that “data from a real-world study revealed that treatment with prescription digital therapeutic Somryst achieved reductions in symptoms of insomnia, anxiety and depression.” Healio adds, “Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia, manufacturer Pear Therapeutics stated in a related press release.” The data from the DREAM study were presented at the SLEEP 2022 meeting. (SOURCE: APA Headlines)